A model needs the components required to answer its particular question. A model that works for one experiment may leave out the biology needed for another.
Tumor models differ in which cancer, stromal and immune components they retain, and those properties can change with the method. A primary organoid study preserved endogenous immune cells and examined checkpoint-blockade responses in that system. This establishes capabilities of a defined model, not a universal ability to predict clinical treatment benefit. The question, retained components, exposure, readout and comparison against relevant observations should accompany a model claim.
Showing the technology this term belongs to: Patient-derived organoids.
Shares Experimental and clinical drug exposure, Drug response and drug sensitivity (IC50, AUC), Evidence from measurement to patient benefit.
Shares Cell composition confound (tumour versus stroma and immune cells), Drug response and drug sensitivity (IC50, AUC), Evidence from measurement to patient benefit.
Shares Cell lines as a proxy for patients, External validation.
Shares Experimental and clinical drug exposure, Evidence from measurement to patient benefit.
Shares Drug response and drug sensitivity (IC50, AUC), External validation.
Shares Experimental and clinical drug exposure, Evidence from measurement to patient benefit.
Shares External validation, Evidence from measurement to patient benefit.
Shares External validation, Evidence from measurement to patient benefit.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/